Journal ArticleDOI
Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors
TLDR
There is a growing understanding of viral, host and environmental factors influencing disease progression, which ultimately could improve the management of chronic hepatitis B.About:
This article is published in Journal of Hepatology.The article was published on 2008-02-01. It has received 1172 citations till now. The article focuses on the topics: HBeAg & Hepatitis B.read more
Citations
More filters
Journal ArticleDOI
Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy
TL;DR: Oral antiviral agents are effective in restoring liver function and improving survival in patients with decompensated cirrhosis especially if therapy is initiated early enough, and entecavir and tenofovir should be considered as the first-line therapy for patients with HBV-related decompensations.
Journal ArticleDOI
Hepatitis B virus genotypes and variants.
Chih-Lin Lin,Jia-Horng Kao +1 more
TL;DR: HBV genotypes and variants may serve as viral genetic markers to predict disease progression as well as help practicing physicians optimize individualized antiviral therapy in clinical practice.
Journal ArticleDOI
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
Roeland Zoutendijk,Jurriën G.P. Reijnders,Fabien Zoulim,Ashley Brown,David Mutimer,Katja Deterding,Wolf Peter Hofmann,Joerg Petersen,Massimo Fasano,Maria Buti,Thomas Berg,Bettina E. Hansen,Milan J. Sonneveld,Heiner Wedemeyer,Harry L.A. Janssen +14 more
TL;DR: When using a threshold of 2000 IU/ml, the association between viral replication and disease progression was reduced, suggesting that complete viral suppression is essential for nucleoside/nucleotide analogue treatment, especially in patients with cirrhosis.
Journal ArticleDOI
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Tung-Hung Su,Jia-Horng Kao +1 more
TL;DR: Oral antiviral therapy may reduce the disease progression of chronic hepatitis B patients and further investigate the efficacy of long‐term entecavir therapy in reduction of the risk of hepatocellular carcinoma, cirrhotic events and mortality in a large group of CHB‐related cirrhosis patients.
Journal ArticleDOI
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.
Pietro Lampertico,Mauro Viganò,Cristina Cheroni,Floriana Facchetti,Federica Invernizzi,Vincenza Valveri,Roberta Soffredini,Sergio Abrignani,Raffaele De Francesco,Massimo Colombo +9 more
TL;DR: IL28B polymorphism is an additional predictor of off‐therapy IFN‐related HBsAg seroclearance to be used in the pretreatment stratification of HBeAg‐negative patients chronically infected by genotype D of HBV.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
Chien-Jen Chen,Hwai I. Yang,Jun Su,C.-L. Jen,San Lin You,Sheng-Nan Lu,Guan-Tarn Huang,Uchenna H. Iloeje +7 more
TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.
Journal ArticleDOI
Chronic hepatitis B
Anna S. Lok,Brian J. McMahon +1 more
TL;DR: These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV).
Journal ArticleDOI
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
TL;DR: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.
Journal ArticleDOI
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
TL;DR: Further studies are needed to investigate other viral factors (eg, HBV genotype/mutant, occult HBV, HIV coinfection) and preventable or treatable comorbidities ( eg, obesity, diabetes) in the HCC risk in cirrhosis.